ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 8c
Tweet
Share
E-mailGet Alerts IBRX Hot Sheet
Join SI Premium – FREE
ImmunityBio, Inc. (NASDAQ: IBRX) reported Q4 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $6.16 million.
For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- GM Defense wins $697.7 million Army contract modification
- Raytheon wins $34 million contract for V-22 software support
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
